Kevin Rich

A specialist in the fields of immunology and biochemistry, Kevin brings a wide-ranging research background gained in both academic institutions and industry to the firm.

During a year-long placement at GSK, Kevin researched genetic modification as a therapeutic option for respiratory diseases. He also spent several months at the University of Auckland, New Zealand, researching within the field of tumour immunotherapy.

Upon returning to the UK to complete his PhD, Kevin studied T-cell signalling within the context of inflammatory bowel disease. He also conducted a sabbatical collaborating between San Francisco General Hospital and the University of California, San Francisco, designing algorithms for automated meta-analyses of patient data.

Upon finishing his PhD, Kevin returned to GSK where he developed immunological assays for use in asthma research and authored a PhD project manuscript in collaboration with the University of Manchester.

Kevin joined Potter Clarkson in June 2018 and works in the biotechnology and pharmaceuticals team.